Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).

The study objective is to determine the real-world safety and effectiveness of Vesemnogene lantuparvovec for the treatment of SMA. The specific objectives are: * To determine clinical effectiveness of Vesemnogene lantuparvovec therapy for SMA as evaluated by developmental gross motor milestone and survival. * To describe the safety profile of Vesemnogene therapy for SMA as evaluated by adverse events reporting and laboratory tests, and monitoring of Adverse events of special interest.

NCT Number	NCT07265232
Lead Sponsor	Lantu Biopharma
Conditions	Spinal Muscular Atrophy (SMA)
Enrollment	15 participants
Start Date	2025-10-15
Primary Completion	2030-10-15 (estimated)
Study Completion	2030-10-15 (estimated)
Updated on ClinicalTrials.gov	2025-12-04